Title | Quality indicators |
---|---|
Process | |
 1 | Breast cancer patients who received mammography or breast ultrasound before surgery |
 2 | Breast cancer patients who had diagnosis in cytology and/or histology before surgery |
 3 | Breast cancer patients who received ER and PR assessment before systemic therapy |
 4 | HER2 assessment before systemic therapy |
 5 | Stage I-II breast cancer patients who underwent breast-conserving surgery |
 6 | Breast cancer patients who received sentinel lymph nodes biopsy |
 7 | Breast cancer patients who received axillary lymph nodes dissection |
 8 | Premenopausal breast cancer patients who were administrated adjuvant chemotherapy |
 9 | Postmenopausal breast cancer patients with high risk who received Adjuvant chemotherapy |
 10 | Breast cancer patients who were administrated at least four cycles of Adjuvant chemotherapy |
 11 | Breast cancer patients treated by trastuzumab in whom heart function was monitored every 3 months |
 12 | Breast cancer patient whose radiotherapy treatment was completed within a 7-week interval from the initiation of radiotherapy after breast-conserving surgery |
 13 | Breast cancer patients who received standard dose of radiotherapy at the whole breast after breast-conserving surgery |
 14 | Breast cancer patients who received adjuvant radiotherapy at chest wall |
 15 | Breast cancer patients who received tamoxifen or aromatase inhibitor treatment |
 16 | Breast cancer patients who received neo-adjuvant chemotherapy |
 17 | Breast cancer patients with hormone receptor status of the tumor stated in Pathology report |
 18 | Breast cancer patients with pathology report stated category of primary tumor and regional lymph nodes with histologic grade |
 19 | Breast cancer patients with pathology report stated number of Examined lymph nodes and positive nodes |
 20 | Breast cancer patients with hormone receptor status of the tumor Stated in pathology report |
 21 | Breast cancer patients with tumor size documented in pathology report |
Management of symptoms or treatment toxicity | |
 22 | Breast cancer patients who were administrated potent anti-emetic therapy |
Communication and Cooperation | |
 23 | Breast cancer patients who were recommended for five-year endocrine treatment |